We further analyzed the relationship between HER3 and patient outcome using Kaplan–Meier estimates up to 33-year follow-up in a series of 8926 total breast cancer patients, of whom 221 showed mutations in the HER3 receptor. Here, ERBB3 is linked to breast carcinoma.